Canada and the European Union have accepted each other's pharmaceutical GMP inspections since February 1, 2003. Canadian cannabis flower has never shared in that arrangement. The Canada-EU Mutual Recognition Agreement on GMP covers drug products only. Cannabis produced under the Cannabis Act sits outside it, so an EU importer can't rely on a Health Canada inspection and every Canadian batch is retested in Europe before release.
That gap adds cost and lead time for every EU buyer sourcing Canadian flower. If you're an importer weighing a Canadian supplier, or an LP pricing its first EU contract, the MRA question is worth settling before anyone signs a quality agreement.
What the Canada-EU MRA covers
The agreement was ratified in September 1998 and became operational on February 1, 2003. In September 2017 its pharmaceutical annex was replaced by the GMP protocol of CETA, the Canada-EU trade agreement that has applied provisionally since September 21, 2017.
Health Canada's published scope lists these product types:
- Human and veterinary pharmaceuticals, prescription and non-prescription
- Human biologicals and radiopharmaceuticals
- Intermediates and bulk pharmaceuticals
- Clinical trial and investigational products
- Natural health products made to a drug-equivalent GMP standard
Active pharmaceutical ingredients, advanced therapy products and plasma-derived products sit outside it for now. Cannabis isn't mentioned anywhere on the page.
For products in scope, the payoff is large. Each side accepts the other's GMP inspections, regulators exchange certificates of GMP compliance, and the EU importer can skip repeat batch testing on arrival. A Canadian drug manufacturer ships into Germany with one inspection and no duplicate lab work. Cannabis LPs get neither.
Why cannabis falls outside the MRA
The MRA rests on drug GMP under the Food and Drug Regulations. Dried flower sold under the Cannabis Regulations is held to Good Production Practices in Part 5 of those regulations instead. GPP is a domestic production standard. It isn't pharmaceutical GMP, and Health Canada doesn't issue a drug GMP certificate for an LP's flower, so there's nothing for an EU authority to recognise.
The two standards overlap on sanitation, pest control and record-keeping. EU-GMP goes further on process validation, change control, a formal pharmaceutical quality system and a Qualified Person's sign-off on every batch. Those are the areas an EU inspector spends most of a site visit on, and they're the areas GPP was never written to cover.
The timing explains it
The CETA GMP protocol took effect in September 2017. The Cannabis Act came into force on October 17, 2018, thirteen months later. The recognition framework was settled before a federal cannabis category even existed, and the published scope has never been widened to include one.
Where LPs get caught
Most of the friction comes from a reasonable assumption. A Health Canada licence, GPP compliance and clean domestic inspections feel like they should count in Germany or Denmark. At the inspection level, they don't. An LP that budgets for EU export expecting its Health Canada record to shorten European quality review is budgeting for the wrong market.
What replaces mutual recognition for EU-bound flower
Without mutual recognition, three EU requirements fill the gap. We call it the EU Entry Stack, because a shipment needs all three before it can be sold.
1. A direct EU-GMP inspection of the Canadian site
An inspectorate from an EU member state, usually the one where the importer holds its authorisation, inspects the Canadian facility against EU-GMP. A pass produces a certificate listed in EudraGMDP, the EU's public GMP database. Buyers should verify the EU-GMP certificate in EudraGMDP rather than accept a PDF.
2. Full batch retesting inside the EU
Article 51 of Directive 2001/83/EC requires each batch imported from a third country to undergo full qualitative and quantitative analysis in a member state. An MRA can waive that step. For Canadian cannabis, nothing waives it, which is why EU retesting often produces COA numbers that differ from the Canadian release results.
3. Qualified Person certification
An EU Qualified Person must certify each batch before it reaches the market. The QP relies on the inspection, the EU test results and the supplier's batch records, so the EU QP batch release process is where weak Canadian documentation surfaces first.
| Factor | Drug product under the MRA | Canadian cannabis flower |
|---|---|---|
| Canadian standard | Food and Drug Regulations GMP | Cannabis Regulations GPP |
| Inspection accepted in EU | Health Canada inspection | EU member state inspection only |
| Import batch testing | Can be waived | Full retest of every batch |
| GMP evidence | Health Canada certificate of compliance | EU certificate in EudraGMDP |
The cultivation stage adds a fourth layer of scrutiny. EU buyers expect flower grown to GACP as the herbal starting material, so an EU-GMP certificate covering packaging alone rarely settles a procurement review. Each layer adds a step to the release timeline, and none of them can be negotiated away in a supply contract.
Canada's other MRAs and what to ask a supplier
Canada also holds MRAs with the United Kingdom, Switzerland, Australia and the EEA-EFTA states. The Canada-UK agreement follows the same drug-product scope as the EU deal. Whichever market you supply, check the scope document of its MRA before relying on the agreement's name. A supplier who cites "the MRA" to explain why a batch won't need retesting has misread it.
Before you sign, ask a Canadian supplier for:
- The EU-GMP certificate number, issuing authority and the activities it covers
- The EU laboratory and QP that will handle release
- Canadian COAs from an ISO/IEC 17025 accredited lab using methods aligned with European pharmacopoeia testing
- GACP evidence for the cultivation site as well as the packaging site
Aligned methods won't remove EU retesting. They shrink the gap between Canadian and EU results, and that gap is what stalls release.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and keep ISO-certified batch data and full traceability records built for the EU retesting and QP release that every European import requires. You can review our certifications and quality documentation before your next sourcing round.
The MRA won't carry Canadian cannabis into Europe. Your documentation has to. If you're planning EU supply for 2027, talk to our export team. Start early.
Frequently Asked Questions
Does the Canada-EU Mutual Recognition Agreement cover cannabis?
No. The agreement covers drug products such as pharmaceuticals, biologicals and drug-standard natural health products. Cannabis produced under the Canadian Cannabis Regulations falls outside its scope, so EU authorities do not accept Health Canada inspections for cannabis flower.
Is Health Canada GPP equivalent to EU-GMP?
They are different standards. Good Production Practices in Part 5 of the Cannabis Regulations sets domestic production rules and was never written as pharmaceutical GMP. Canadian cannabis entering the EU medical channel needs EU-GMP certification from an EU member state inspectorate.
Why is Canadian cannabis retested when it arrives in the EU?
Article 51 of Directive 2001/83/EC requires full qualitative and quantitative analysis in a member state for each batch imported from a third country. A mutual recognition agreement can waive that step, but none applies to Canadian cannabis.
Who inspects a Canadian cannabis facility for EU-GMP?
An inspectorate from an EU member state, usually the country where the importer holds its authorisation. A successful inspection produces an EU-GMP certificate that appears in the EudraGMDP database.
Does the Canada-UK MRA cover cannabis?
The Canada-UK agreement follows the same drug-product scope as the Canada-EU agreement, so cannabis produced under the Cannabis Regulations falls outside it. UK importers apply their own import and quality requirements.
